ABSTRACT
A 43-yr-old woman with recently diagnosed breast carcinoma presented with a right pleural effusion after a cycle of adjuvant, high-dose chemotherapy supported by peripheral blood progenitor cells (PBPC) and granulocyte-colony-stimulating factor (G-CSF, Filgrastim). Cytologic examination of the pleural aspirate yielded highly cellular material composed predominantly of cells of myeloid and macrophage/monocytic lineages. Despite clinical concern of a malignant effusion, the combination of cytologic and immunophenotypic examination yielded the correct diagnosis of a nonneoplastic effusion related to underlying pleural inflammation and possibly the administration of G-CSF.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/therapy , Granulocyte Colony-Stimulating Factor/adverse effects , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/drug effects , Pleural Effusion/chemically induced , Adult , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Cyclophosphamide/administration & dosage , Cytodiagnosis , Epirubicin/administration & dosage , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cells/pathology , Humans , Immunohistochemistry , Macrophages/immunology , Macrophages/pathology , Monocytes/immunology , Monocytes/pathology , Neoplasm Staging , Pleural Effusion/pathology , Recombinant ProteinsABSTRACT
Hypoglycemic rats bearing insulin-secreting islet-cell adenomas produced by the combined action of streptozotocin and nicotinamide were treated with streptozotocin. Antitumor response was demonstrated by elevation of blood glucose, reduction in plasma and tumor IRI, and histopathologic changes in the beta-cell neoplasm. The rodent tumor model may serve as a predictive system for selection and investigation of mechanisms of action of future antitumor agents to be used in the treatment of malignant insulinoma in man.
Subject(s)
Adenoma, Islet Cell/drug therapy , Streptozocin , Adenoma, Islet Cell/chemically induced , Adenoma, Islet Cell/pathology , Animals , Blood Glucose/metabolism , Insulin/blood , Niacinamide , Rats , Streptozocin/therapeutic useABSTRACT
The renal oncogenic activity of streptozotocin in male Holtzman rats was significantly decreased by nicotinamide. Adenomas of the kidney were noted in 77% (21/28) of the animals treated with single iv dose of the streptozotocin, 50 mg/kg, while only 18% (5/28) of animals given nicotinamide ip, 350 mg/kg, 10 min before and 180 min after the same dose of streptozotocin had demonstrable renal tumors. Moreover, the renal adenomas induced by streptozotocin alone occurred sooner and were generally larger when compared with those in the animals treated with the nicotinamide-streptozotocin combination. The 50 mg/kg dose of streptozotocin was diabetogenic in all rats, but the diabetic state was not permanent. Spontaneous recovery from the diabetes was first noted after 8 and 10 months of followup, and after 16 months none of the surviving rats were diabetic.
